Trial Profile

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jul 2025 According to an Eli Lilly and Company media release, the company announced that ZEPBOUND™ KwikPen (tirzepatide injection) the first and only injection for the treatment of obesity has approved by Health Canada and available in Canada.
29 May 2025 According to Eli Lilly and Company media release, company announced that data from this study will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.
01 May 2025 Results (n=255) from substudy of this trial performed for participants with obesity or overweight from the SURMOUNT-1 trial were published in the Diabetes, Obesity and Metabolism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com